Avalo Therapeutics (AVTX) Stock Price, News & Analysis

Company Overview

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction. These clinical and preclinical assets are supported by a broader research portfolio exploring additional targets in inflammation, tissue remodeling and metabolic regulation. Avalo conducts in-house research at its headquarters in Redwood City, California, and collaborates with academic and industry partners across North America and Europe.

Founded in 2014, Avalo Therapeutics has assembled a management team with deep expertise in drug discovery, clinical development and commercialization. The leadership includes executives and scientists who have held senior roles at leading pharmaceutical and biotechnology firms, providing strategic guidance and operational experience as the company advances its pipeline. Avalo’s governance structure and advisory board further support rigorous scientific evaluation and cultural alignment with industry best practices.

With its integrated research capabilities, external partnerships and a focused pipeline of innovative candidates, Avalo Therapeutics aims to advance multiple programs toward late-stage clinical trials and ultimately deliver new treatment options for patients suffering from chronic cardiometabolic and inflammatory disorders.

Key Stats

• Today's Range: $10.51 to $12.41
• 50-Day Range: $4.75 to $11.60
• 52-Week Range: $3.39 to $16.00
• Volume: 362,485 shs
• Average Volume: 211,948 shs
• Market Capitalization: $152.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Avalo Therapeutics Stock Analysis - MarketRank™

Avalo Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 358th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Avalo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Avalo Therapeutics has a consensus price target of $30.00, representing about 158.6% upside from its current price of $11.60.

Amount of Analyst Coverage

Avalo Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avalo Therapeutics are expected to grow in the coming year, from ($19.07) to ($4.70) per share.

Price to Book Value per Share Ratio

Avalo Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.86% of the float of Avalo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avalo Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalo Therapeutics has recently increased by 117.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avalo Therapeutics does not currently pay a dividend.

Dividend Growth

Avalo Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.86% of the float of Avalo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Avalo Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avalo Therapeutics has recently increased by 117.35%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.10

News Sentiment

Avalo Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for AVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.03% of the stock of Avalo Therapeutics is held by insiders.

Percentage Held by Institutions

87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVTX Stock Analysis - Frequently Asked Questions

How have AVTX shares performed this year?

Avalo Therapeutics' stock was trading at $7.43 at the beginning of 2025. Since then, AVTX shares have increased by 56.1% and is now trading at $11.60.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.49.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split before market open on Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Who are Avalo Therapeutics' major shareholders?

Top institutional investors of Avalo Therapeutics include BVF Inc. IL (7.82%), Nantahala Capital Management LLC (7.57%), Affinity Asset Advisors LLC (4.62%) and Bank of America Corp DE (3.09%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, June Sherie Almenoff and Christopher Ryan Sullivan.
View institutional ownership trends.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avalo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVTX
• CIK: 1534120
• Web: www.avalotx.com
• Phone: (410) 522-8707
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Avalo Therapeutics: $30.00
• High Price Target: $48.00
• Low Price Target: $15.00
• Potential Upside/Downside: +158.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.13 million
• Net Margins: N/A
• Pretax Margin: -10,451.70%
• Return on Equity: -48.48%
• Return on Assets: -35.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.44
• Quick Ratio: 12.44

Sales & Book Value

• Annual Sales: $440 thousand
• Price / Sales: 346.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.80 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 13,150,000
• Free Float: 12,753,000
• Market Cap: $152.54 million
• Optionable: Not Optionable
• Beta: 0.88